Rafael Holdings (RFL) – Hot FDA News
-
Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
-
Rafael Holdings (RFL) Announces CPI-613 Did Not Meet Primary Endpoints in Phase 3 Trial
Back to RFL Stock Lookup
